Landscapes / Companies
Phanes Therapeutics not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 in Phase 2
Drugs
3
in active trials
Trials
3 active
3 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Artificial immunoglobulin |
Phase 1/2 | Dec 2027Phase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 1/2 | Dec 2027Phase 1/2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) and 4 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 1/2 | Dec 2027Phase 1/2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma and 2 more | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021